Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

CCR2 acts as scavenger for CCL2 during monocyte chemotaxis.

Volpe S, Cameroni E, Moepps B, Thelen S, Apuzzo T, Thelen M.

PLoS One. 2012;7(5):e37208. doi: 10.1371/journal.pone.0037208. Epub 2012 May 17.

2.

Recent developments in CCR2 antagonists.

Xia M, Sui Z.

Expert Opin Ther Pat. 2009 Mar;19(3):295-303. doi: 10.1517/13543770902755129. Review.

PMID:
19441905
3.

A CCL2-based fusokine as a novel biopharmaceutical for the treatment of CCR2-driven autoimmune diseases.

Rafei M, Galipeau J.

Crit Rev Immunol. 2010;30(5):449-61. Review.

PMID:
21083526
4.

The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases.

Conductier G, Blondeau N, Guyon A, Nahon JL, Rovère C.

J Neuroimmunol. 2010 Jul 27;224(1-2):93-100. Review.

PMID:
20681057
5.

Monocyte-mediated defense against microbial pathogens.

Serbina NV, Jia T, Hohl TM, Pamer EG.

Annu Rev Immunol. 2008;26:421-52. doi: 10.1146/annurev.immunol.26.021607.090326. Review.

6.

[FROUNT, a regulator of monocytes/macrophage chemotaxis].

Toda E, Terashima Y.

Seikagaku. 2007 Oct;79(10):972-5. Review. Japanese. No abstract available.

PMID:
18027578
7.

Leukocyte chemoattractant receptors in human disease pathogenesis.

Zabel BA, Rott A, Butcher EC.

Annu Rev Pathol. 2015;10:51-81. doi: 10.1146/annurev-pathol-012513-104640. Epub 2014 Oct 24. Review.

PMID:
25387059

Supplemental Content

Support Center